Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
The Journal of Pharmacology and Experimental Therapeutics|November 23, 2011
Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophilsRoy Pettipher, Shân L Vinall, Luzheng Xue, et al.
The Prostate|July 23, 2005
Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cellsClifford G Tepper, Jeffrey P Gregg, Xu-Bao Shi, et al.
Genes & Cancer|July 7, 2016
Decreased expression of let-7c is associated with non-response of muscle-invasive bladder cancer patients to neoadjuvant chemotherapyRuth L Vinall, Clifford G Tepper, Alexandra A Z Ripoll, et al.
The Journal of Allergy and Clinical Immunology|December 3, 2014
Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalkLuzheng Xue, Joannah Fergusson, Maryam Salimi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2011
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3Liqun Chen, Benjamin A Mooso, Maitreyee K Jathal, et al.
Oncogene|July 27, 2007
Inappropriate activation of androgen receptor by relaxin via beta-catenin pathwayS Liu, R L Vinall, C Tepper, et al.
Oncogene|July 27, 2017
The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancerL S D'Abronzo, S Bose, M E Crapuchettes, et al.
Endocrine-Related Cancer|September 21, 2012
Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localizationBenjamin A Mooso, Ruth L Vinall, Clifford G Tepper, et al.
Pageof 3